How MSI and TMB Factor into Current Biomarker Testing PanelsVideo Categories: 2018 ASCO Insights, Biomarkers, and Video Library
Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”
Dr Agarwala provides his perspective on the importance of the Global Biomarkers Consortium, World Cutaneous Malignancies Congress and the journal Personalized Medicine in Oncology.
Dr. Michaelis discusses what approaches she takes for PV patients with unmet clinical needs such as recurrent thrombosis or hemorrhage. Supported through funding from Incyte